Free Republic 2nd Qtr 2021 Fundraising Target: $88,000 Receipts & Pledges to-date: $31,620
35%  
Woo hoo!! And we're now over 35%!! Thank you all very much!! God bless.

Keyword: clinicaltrial

Brevity: Headers | « Text »
  • Novavax Vaccine Trial Indicates 100% Protection Against Severe COVID-19 Due to South African Variant

    05/07/2021 8:25:28 AM PDT · by Red Badger · 14 replies
    https://scitechdaily.com ^ | By UNIVERSITY OF THE WITWATERSRAND MAY 6, 2021
    The New England Journal of Medicine (NEJM) published findings of the Phase 2b clinical trial conducted in South Africa. NEJM is recognized as the world’s leading medical journal. Shabir Madhi, Professor of Vaccinology, co-author of the study, and the Director of the Vaccines & Infectious Diseases Analytics Research Unit (Wits VIDA), led the Novavax Covid-19 vaccine trial in South Africa. The published data provide additional detail of an initial analysis conducted in January, while more robust data from a complete analysis of the study was subsequently shared in March 2021. Publication of initial primary analysis highlights cross-protection by the Novavax...
  • Human Organ Chips Shift Amodiaquine from Old Antimalarial to Promising COVID-19 Treatment

    05/04/2021 1:55:19 PM PDT · by RC one · 23 replies
    As the COVID-19 pandemic continues, the pace of vaccine development has surpassed anyone’s wildest expectations. Unfortunately, drug development for treatments has not kept the same pace. Indeed, there are still very few effective treatments for COVID-19. Now, a collaboration between four research institutes has identified the antimalarial drug amodiaquine as a potent inhibitor of SARS-CoV-2 infection in human lung cells and in living preclinical models. This breakthrough helped secure the inclusion of amodiaquine in a COVID-19 clinical trial that is currently underway in 13 different countries in Africa where this drug is inexpensive and widely available.The research is published in...
  • Pfizer: Single pill cure for COVID-19 could be available this year

    05/03/2021 12:45:39 PM PDT · by nickcarraway · 36 replies
    KLFY ^ | Apr 26, 2021
    Drugmaker Pfizer is currently testing a single pill cure for COVID-19, and if all goes well, the drug could be available this year. The drug, called PF-07321332, is currently in a Phase One clinical trial with healthy adults. According to the Telegraph, the protease inhibitor may be available as soon as this year. The pill was unveiled at the American Chemical Society Spring 2021 meeting in early April. The drug works by targeting the main protease of SARS-CoV-2, the virus that causes COVID-19. By inhibiting the protease, the drug prevents the virus from reproducing itself within the body. CDC changes...
  • Clinical trial conducted by MedinCell confirms the safety of continuous administration of Ivermectin in Montpellier, France

    05/01/2021 8:39:50 PM PDT · by SeekAndFind · 17 replies
    MEDINCELL ^ | 04/19/2021
    * Clinical trial validates the safety of ivermectin taken daily in oral form, to simulate the continuous release of the active substance by a long-acting injection.* No side effects were observed with the three doses of ivermectin tested up to 100 µg / kg.* MedinCell develops several long-acting injectable formulations of ivermectin, the most advanced aims at preventing infection from Covid-19 and its mutants for several months.Positive results of the safety study"All our programs are developed in accordance with the highest ethical standards and on the basis of reliable scientific principles with a view to potential massive deployment. Proving the...
  • 6-month Ivermectin clinical trial for Covid-19 to start in the Philippines

    04/20/2021 9:22:24 PM PDT · by SeekAndFind · 16 replies
    President Rodrigo Duterte has ordered the conduct of a clinical trial of the anti-parasitic drug ivermectin for use as a possible treatment against COVID-19. Science and Technology Secretary Fortunato dela Peña said he is planning to tap Dr. Aileen Wang of the Philippine General Hospital – UP Manila to lead the clinical trial that could last for six months. “The minimum period would be six months because the process is rigorous, except if we will have several people to volunteer, then that will speed up the process,” Dela Peña said. He said a quarantine center near PGH will be used...
  • Clinical trial confirms breakthrough treatment for COVID-19: Patients with a self-administered nasal spray found to have reduced SARS-CoV-2 viral load by more than 95% in infected participants within 24 hours

    04/16/2021 7:44:44 PM PDT · by SeekAndFind · 45 replies
    Premium Times ^ | 04/16/2021
    Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant.ADVERTISEMENTPatients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hoursTrial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placeboRandomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variantNo adverse events were recorded in the groupSubmission for Emergency Use in the UK and Canada for the treatment...
  • NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

    03/29/2021 9:19:32 AM PDT · by rxsid · 11 replies
    prnewswire.com ^ | 03.29.2021 | NeuroRx
    NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 RADNOR, Pa., March 29, 2021 /PRNewswire/ -- NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF,OTCQB:RLFTF). Across all patients and sites, ZYESAMI™ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and...
  • Experimental Alzheimer's drug could slow cognitive decline in patients, early results suggest

    03/26/2021 8:03:09 AM PDT · by bitt · 15 replies
    CNN.COM ^ | 3/13/2021 | Lauren Mascarenhas
    Eli Lilly and Company's experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer's disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday. The study included 257 patients with early symptomatic Alzheimer's disease; 131 received donanemab, while 126 received a placebo. The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer's patients by 32% after 76 weeks, compared to those who received a placebo. Taken over 18 months, that 32% slowing of decline could be noticeably impactful for Alzheimer's patients, noted Maria Carrillo, chief science...
  • AstraZeneca Releases 'Outdated and Potentially Misleading Data' on Covid-19 Vaccine Trial

    03/23/2021 6:18:55 PM PDT · by SeekAndFind · 24 replies
    PJ Media ^ | 03/23/2021 | Rick Moran
    AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, must think we Americans are a bunch of ignorant rubes. After the company finally released results from its vaccine’s Stage 3 Trials, U.S. regulators were shocked to discover that the information was “outdated and potentially misleading.” The rosy picture the company painted of its vaccine on Monday — that it had a 79 percent efficacy against COVID-19 and substantially reduced serious illness — turns out to have been more PR than real. Stat: In a statement issued soon after midnight Tuesday morning, the National Institute of Allergy and Infectious Diseases said it...
  • Medical Doctor and Study Coordinator Sentenced to Prison in Scheme to Falsify Clinical Trial Data

    03/22/2021 2:56:46 PM PDT · by SecAmndmt · 22 replies
    Justice News ^ | March 22, 2021 | US Dept of Justice
    (...) Medical Doctor and Study Coordinator Sentenced to Prison in Scheme to Falsify Clinical Trial Data A Florida medical doctor was sentenced to 63 months in prison after pleading guilty to her role in a scheme to falsify clinical trial data regarding an asthma medication. Dr. Yvelice Villaman Bencosme, 64, of Miami, previously pleaded guilty in U.S. District Court for the Southern District of Florida to one count of conspiracy to commit wire fraud related to her work at Unlimited Medical Research in Miami. Bencosme is the second defendant to be sentenced in connection with the scheme. On March 5,...
  • Promising At-Home Treatment for COVID-19 Discovered: FDA Approved Drug for Leprosy

    03/16/2021 11:36:24 AM PDT · by Red Badger · 15 replies
    https://scitechdaily.com ^ | MARCH 16, 2021 | By SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Testing in the lab at Sanford Burnham Prebys Medical Discovery Institute. Credit: Sanford Burnham Prebys Medical Discovery Institute Phase 2 clinical trial could begin immediately for clofazimine, an FDA-approved drug on WHO’s List of Essential Medicines. A Nature study authored by scientists at Sanford Burnham Prebys Medical Discovery Institute and the University of Hong Kong shows that the leprosy drug clofazimine, which is FDA approved and on the World Health Organization’s List of Essential Medicines, exhibits potent antiviral activities against SARS-CoV-2 and prevents the exaggerated inflammatory response associated with severe COVID-19. Based on these findings, a Phase 2 study evaluating...
  • Novavax vaccine 96% effective against original coronavirus version in UK trial

    03/12/2021 7:17:07 AM PST · by Eleutheria5 · 14 replies
    Yahoo! ^ | 11/3/21 | Dania Nadeem and Carl O'Donnell
    Novavax Inc's COVID-19 vaccine was 96% effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on Thursday, moving it a step closer to regulatory approval. The vaccine was also about 86% effective in protecting against the more contagious virus variant first discovered and now prevalent in the UK. It was only around 55% effective in a separate, smaller trial in South Africa, where volunteers were primarily exposed to another newer, more contagious variant that is widely circulating there and spreading around the world. In both...
  • Israel's Sheba Medical Center Researcher: Antiparasitic drug Ivermectin reduces length of COVID-19 infection in double-blind, placebo-controlled study

    03/01/2021 12:54:32 PM PST · by SeekAndFind · 28 replies
    Jerusalem Post ^ | 02/14/2021 | MAAYAN JAFFE-HOFFMAN
    An Israeli tropical-disease expert says he has new proof that a drug used to fight parasites in third-world countries could help reduce the length of infection for people who contract coronavirus. Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center in Tel Hashomer, last week completed a clinical trial of the US Food and Drug Administration-approved drug Ivermectin, a broad-spectrum antiparasitic agent that has also been shown to fight viruses. The double-blind, placebo-controlled study included 100 people with mild to moderate cases of the disease who were not hospitalized for the virus....
  • 'Game-Changer' Drug Promotes Weight Loss Like No Medicine Ever Seen, Scientists Say

    02/11/2021 11:05:40 AM PST · by Red Badger · 77 replies
    https://www.sciencealert.com ^ | PETER DOCKRILL | 11 FEBRUARY 2021
    In the simplest terms, obesity is the product of a body's energy output being less than its energy input. But in reality, there's nothing simple about this complex and mysterious disease. Obesity, which has skyrocketed in recent decades – now defining the body mass of over 40 percent of adult Americans – isn't just difficult for people to endure and scientists to understand. It's also incredibly hard to treat. Beyond commitment to sustained lifestyle changes – healthy eating and exercise, effectively – there are really only two potential options that may help: bariatric surgery and weight-loss medications. The former is...
  • Ivermectin to undergo rigorous clinical trial as Covid treatment

    02/08/2021 5:07:37 AM PST · by MtnClimber · 105 replies
    American Thinker ^ | 8 Feb, 2021 | Thomas Lifson
    The cheap, generic, anti-parasite drug Ivermectin finally is to undergo rigorous clinical trials in a first world nation for use in fighting Covid-19. The cheap, generic, anti-parasite drug Ivermectin finally is to undergo rigorous clinical trials in a first world nation for use in fighting Covid-19. Japan has been hit with a second wave of Covid cases, and as result, the Tokyo Metropolitan Government (population: 13.8 million) is looking for approaches which could minimize stress on available hospital beds. Nikkei Asia reports (Nikkei is Japan’s leading busines daily, comparable to the Wall Street Journal): The Tokyo Metropolitan Government plans to...
  • New Israeli Drug Cured 29 of 30 Seriously-Ill COVID-19 Patients

    02/05/2021 2:46:05 PM PST · by george76 · 28 replies
    PJ Media ^ | FEB 05, 2021 | RICK MORAN
    A new coronavirus treatment developed at Tel Aviv’s Ichilov Medical Center appears to have cured 29 of 30 moderately-ill and seriously-ill COVID-19 patients, the hospital said. The patients were released within 3 to 5 days of being treated.. This was only the first stage of trials and many months and thousands of patients will have to be treated before anything definitive can be said about the treatment. But the drug apparently works on the immune system to prevent a cytokine storm, which often leads to critical illness and death. Nadir Arber, the professor who invented the potential treatment, hailed the...
  • Encouraging Results on Ivermectin Clinical Trial for Reducing Mild COVID-19

    01/19/2021 4:40:40 PM PST · by FreedomForce · 15 replies
    ScitechDaily ^ | January 19, 2012 | BARCELONA INSTITUTE FOR GLOBAL HEALTH
    A small pilot study suggests that early administration of ivermectin can reduce viral loads and symptom duration in patients with mild COVID-19, which in turn could help reduce viral transmission. The study, which is part of the SAINT project and has been led by the University of Navarra Clinic and the Barcelona Institute for Global Health (ISGlobal), an institution supported by the “la Caixa” Foundation, warrants further exploration in larger clinical trials. The findings of the pilot study have been published in EClinicalMedicine, a clinical journal published by The Lancet.
  • Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial (8.5X better)

    12/14/2020 11:55:01 AM PST · by ConservativeMind · 10 replies
    Molecular Nutrition & Food Research ^ | March 10, 2015 | Jessica L. Cooperstone, Robin A. Ralston, Ken M. Riedl, Thomas C. Haufe, et al
    Epidemiological evidence suggests that diets rich in tomatoes and tomato products may be protective against risk for certain cancers, especially prostate cancer. The carotenoid lycopene has received the most attention as the compound in tomatoes responsible for this noted decrease in cancer risk. In raw, red tomatoes, approximately 95% of the total lycopene is present in the all-trans form. Despite the predominance of dietary all-trans-lycopene, cis-isomers account for 58-73% of total lycopene in human serum, and a surprisingly high 79-88% in benign or malignant prostate tissue. This observation is related to isomerization in vivo, as demonstrated by conventional and tracer...
  • How NOT to Conduct a Covid-19 Clinical Trial: Oxford Research Reveals High Mortality & Flawed Therapeutic Response – It Reveals Nothing New about Hydroxychloroquine

    07/16/2020 8:48:25 AM PDT · by SeekAndFind · 3 replies
    Covexit: Covid-19 News and Policy Analysis ^ | 07/16/2020 | Jean-Pierre Kiekens
    Since mid-March, early treatments were known to have great potential as a cure for COVID-19. Dr Zelenko was already treating his patients in NY State with his tri therapy combining HCQ with Azithromycin and Zinc. The first study by Professor RaoultÂ’s team, showing a dramatic reduction in the viral load for patients treated early with HCQ and Azithromycin was published on March 20. First Study About Efficacy of Hydroxychloroquine With or Without Azithromycin for Treating COVID-19 In a March 28 detailed article, communicated to those in charge of the Oxford trial, I expressed serious concerns about the RECOVERY trial...
  • FDA to allow using plasma taken from COVID-19 patients to examine whether it contains antibodies

    03/25/2020 12:13:59 AM PDT · by nickcarraway
    WPTV ^ | Mar 24, 2020 | Justin Boggs
    The FDA said on Tuesday it has developed guidelines to take plasma from coronavirus survivors to treat patients who are critically ill from the virus. The FDA said on Tuesday that It is possible that convalescent plasma contains antibodies to the coronavirus and might be effective against the infection. The FDA said that although the announcement is promising, convalescent plasma has not been shown to be effective in every disease studied. The FDA is not approving using plasma as a treatment, instead using it as a clinical trial and for the treatment of those who are critically ill. "Given the...